The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The artificial intelligence (AI) boom has taken the stock market by storm. The S&P 500 (SNPINDEX: ^GSPC) has advanced 55% in ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in cystic fibrosis, cancer and possibly chronic pain.

TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet at the campus. The cell therapy biotech is moving to its own dedicated lab ...

The stock's fall snapped a three-day winning streak.

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

Arish Global Services has emerged as one of the leading providers in web lead generation, offering a comprehensive suite of ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.